Skip to main content

NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on providing testing solutions to hospital and commercial reference laboratories, announced today its plans for a SARS-Cov-2 Assay for use on its high throughput, fully automated NeuMoDx 288 and 96 Molecular Systems. SARS-Cov-2 is the Coronavirus that has been determined to cause COVID-19 infections.

Read Article